Virta Health has released a peer-reviewed publication which details 1-year results from its ongoing clinical trial, now 2.5 years in duration. The study augments Virta Health’s existing body of peer-reviewed research, which proved that the Virta Treatment could systematically reverse type 2 diabetes in as little as 10 weeks.
Newly released data demonstrates that diabetes reversal rates are sustained and in fact improved at one year, while metrics of other chronic conditions, such as obesity, high blood pressure, cardiovascular disease and inflammation, are also substantially improved.
“What’s exciting about this new data is that the results are demonstrably sustainable, and the Virta Treatment is proving to simultaneously improve other comorbidities, such as blood pressure, inflammation and heart disease,” said Sami Inkinen, CEO and Co-Founder of Virta Health. “I am more excited than ever about what this means for our current and future patients, not to mention the impact we can make on the economic burden of chronic disease as we scale towards our long-term goal of reversing type 2 diabetes in 100 million people by 2025.”
By combining highly-individualized nutritional ketosis, medical supervision, and innovations in technology and artificial intelligence, the Virta Treatment helps people eliminate medications safely and sustainably while simultaneously lowering blood sugar and restoring metabolic health. Virta’s continuous remote care model—near real-time access to physicians and other clinical team members via a mobile device—allows for scale to millions of people like Larry, who is making type 2 diabetes a thing of the past.
Enterprises, such as Virta customer Purdue, are benefitting by creating a healthier workforce and experiencing significant savings for each employee receiving the Virta Treatment.
Key Study Findings:
The study, published in the peer-reviewed healthcare journal Diabetes Therapy, evaluates health outcomes after 1 year for 262 adults with diagnosed type 2 diabetes who received the Virta Treatment, and an additional 87 adults with type 2 diabetes who received usual care from their doctors and diabetes educators. Key findings of the Virta Treatment group at 1-year include:
- 60 percent of those completing one year had type 2 diabetes reversed (HbA1c < 6.5% while taking no glycemic control medications or only metformin).
- 83 percent remained enrolled in the trial.
- 94 percent of insulin users reduced or stopped usage altogether.
- Participants experienced 1.3 percent average reduction in HbA1c (while reducing or eliminating medications).
- Participants achieved 12 percent weight loss on average
Usual care participants had no significant changes to HbA1c, weight or diabetes medicine use. With the Virta Treatment, however, results go beyond blood sugar and obesity reduction and included the following statistically significant changes:
- 24 percent decrease in triglycerides
- 18 percent increase in HDL-C (i.e. ‘good’ cholesterol)
- 39 percent decrease in C-reactive protein (a marker of inflammation)
- Decrease in both systolic and diastolic blood pressure
To learn more about the Virta Treatment and to view the full results of the 1-year study, please visit www.virtahealth.com
